Arsenic trioxide As₂O₃
Also known as: Arsenic Sesquioxide Arsenic Oxidearsenous Trioxide

Therapeutic indications

Arsenic trioxide is indicated for:

Acute promyelocytic leukaemia

Population group: both men and women, only adults (18 years old or older)

Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:

  • Νewly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 × 103/µl) in combination with all-trans-retinoic acid (ATRA)
  • Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: TRISENOX Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈